

Ref: 21-556

Freedom of Information Request

20 October 2021

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

We can confirm that we hold some the information you are requesting

Question 1

What guidelines or protocols do you refer to regarding the management of patients with:

Systemic lupus erythematosus (SLE)

British Society of Rheumatology 201, 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Lupus nephritis (LN)

American College of rheumatology guidelines for screening, treatment, management of lupus nephritis.

Question 2

Please detail the number of patients that were admitted as an inpatient or day case in the last 12 months for the following primary diagnosis:

	Diagnosis (ICD10 code)
Patient number and care setting	Systemic lupus erythematosus with organ or system involvement
	(M321)
Inpatient admission	(M321) Approx 5 - 10

Systemic lupus erythematosus with organ or system involvement (M321)

Question 3

Do you refer patients within the ICD10 code M321 to another Trust?

If you answered 'Yes', please detail which Trusts you refer patients to.

North Bristol NHS Trust, to the renal department

Question 4

Is there a specific clinic for LN patients at your Trust?

No

Question 5

Please complete the number of patients prescribed with the following products in the last 12 months within the ICD10 code Systemic lupus erythematosus with organ or system involvement (M321):

Diagnosis (ICD10 code)	
Product	Systemic lupus erythematosus with organ or system involvement (M321)
Azathioprine	347
Belimumab	*
Ciclosporin	554
Cyclophosphamide	430
Mycophenolate mofetil	602
Oral tacrolimus	213

This was calculated by checking people who were given these prescriptions against inpatient admission data for the last 10 years to check for a Lupus diagnosis code of M32.1D.

Please note: Where the figures are between 1 and 5, this has been denoted by *. Due to the low numbers, we have considered that there is the potential for individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. The Trust therefore finds that the Section 40(2) exemption contained within the Freedom of information Act 2000 is engaged. (Section 40 is the exemption for personal information).

Question 6

Has a shared care agreement/arrangement been established between your institution and primary care for the treatment of lupus nephritis?

Yes

If you answered 'Yes', which of the following medicines can be prescribed within the shared care agreement? Yes/No

	Ciclosporin	Cyclophosphamide	Mycophenolate	Oral
Azathioprine			mofetil (MMF)	tacrolimus
Yes/No	Yes	No	No	No

Question 7

Has a shared care agreement/arrangement been established between your institution and a tertiary centre for the treatment of lupus nephritis? If so, please specify what medicines can be prescribed in secondary care within these shared care agreements. Not specifically for lupus nephritis, we are a specialised centre for CTD and vasculitis therefore can prescribe Rituximab and Belimumab and cyclophosphamide but for lupus nephritis we

Question 8

What is the name of your local integrated care system?

would discuss with the renal team at North Bristol Trust.

We do not hold this information, led by renal team at North Bristol Trust. please contact their FOI team foi@nbt.nhs.uk

Question 9

For the LN patient pathway, is care commissioned by:

	Block contract	Blended payment
Activity		
Yes		
No		

Not commission for lupus nephritis specifically as led by renal team at North Bristol Trust, please contact their FOI team foi@nbt.nhs.uk

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance University Hospitals Bristol and Weston NHS Foundation Trust Trust Headquarters Marlborough Street Bristol BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be

contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click here.

Yours sincerely

Freedom of Information Team University Hospitals Bristol and Weston NHS Foundation Trust